Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.

Jasmine S SukumarSagar SardesaiAndy NiNicole WilliamsKai JohnsonDionisia QuirogaBhuvana RamaswamyRobert WesolowskiMathew CherianDaniel G StoverMargaret Gatti-MaysAshley PariserPreeti SudheendraMridula A GeorgeMaryam Lustberg

Published in: Cancer medicine (2024)

This is the first real-world study evaluating ET treatment patterns in HR+/HER2+ premenopausal BC. OS use was uncommon and the majority received tamoxifen as the preferred ET regardless of most clinicopathologic risk factors. Additional research is needed to optimize ET decisions in young women with this distinct BC subtype.

Keyphrases

risk factors
postmenopausal women
early stage
stem cells
replacement therapy
young adults
bone marrow
estrogen receptor
early breast cancer